01 1Cadila Pharmaceuticals
01 1ESCITALOPRAM OXALATE USP
01 1India
01 1Active
01 1Complete
GDUFA
DMF Review : Complete
Rev. Date : 2014-09-23
Pay. Date : 2013-09-30
DMF Number : 22440
Submission : 2009-01-06
Status : Active
Type : II
20
Cadila Pharmaceuticals Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is ESCITALOPRAM OXALATE USP, with a corresponding US DMF Number 22440.
Remarkably, this DMF maintains an Active status since its submission on January 06, 2009, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of September 23, 2014, and payment made on September 30, 2013, indicating their dedication to facilitating drug approvals, Categorized as Type II
